Möchten Sie immer auf dem neuesten Stand bleiben?

Gigamon is recognized as the leading vendor in the deep observability market with 51 percent market share in 2025 by 650 Group.

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Heart disease is often linked to lifestyle factors like diet and exercise, but a lesser-known genetic risk impacts millions of people. According to...

New research from Momentive Software finds growth path visibility and technology efficiency are critical to workforce stability in mission-driven sector.

Marvel Biosciences secures $600,000 in non-dilutive funding from Alberta Innovates to support Phase I clinical trials of its autism-focused patented MB-204

NEW YORK, March 28, 2026 (GLOBE NEWSWIRE) -- Cointelegraph Research has released a new analysis examining how the United Nations Development Programme (UNDP) is testing blockchain technology to...

Nonpartisan research firm provides data for ABC News, CNN, The Associated Press, and other major networks

PALO ALTO, CA, March 25, 2026 (GLOBE NEWSWIRE) -- Today, the Latino Business Action Network (LBAN), in collaboration with the Stanford Graduate School of Business (GSB), released the 11th Annual...

Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204, lead asset discovery, a patented neuroactive adenosine A2A antagonist

Intended audience: global business, financial and trade media HERNEXEOS® (zongertinib) and JASCAYD® (nerandomilast) launched in H2, 2025Group net sales increased 7.3%* to EUR 27.8 billion in...

The goal is to strengthen our intellectual property and to better understand how PRP technology can overcome resistant tumors and age-related diseases.